Articles from Avilar Therapeutics

Avilar Therapeutics, a biopharmaceutical company pioneering extracellular protein degradation through its ATAC (ASGPR Targeting Chimera) platform, today announced the appointment of Leslie Meltzer, Ph.D. as Chief Executive Officer. Dr. Meltzer will also join Avilar's Board of Directors.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,819,551 on November 21, 2023. The issued patent provides broad protection for Avilar’s first wave of extracellular proteins degraders called ATACs (ASGPR Targeting Chimeras) with therapeutic applications in a wide range of human diseases. ATACs are bi-functional molecules that leverage Avilar’s advanced chemistry for creating high-affinity ligands to the asialoglycoprotein receptor (ASGPR) and are designed to shuttle pathogenic extracellular proteins from circulation into the endolysosome where the unwanted proteins are degraded.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present new preclinical data from its ATAC (ASGPR Targeting Chimera) degrader platform at the sixth annual Targeted Protein Degradation Summit being held in Boston on October 30 – November 2, 2023.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that its company leaders will participate in two upcoming industry conferences, highlighting the company’s proprietary protein degradation platform capabilities and associated opportunities to target historically intractable pathogenic proteins. Avilar will present on the degradation of extracellular proteins using ASGPR targeting chimeras (ATACs) at Promega’s Targeted Protein Degradation Symposium taking place in Madison, Wisconsin on September 20 – 21, 2023. Avilar will also participate in a panel discussion on partnerships and investment at the Next-Generation Undruggable Summit being held in Boston, Massachusetts on October 3, 2023.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Adam Muzikant, Ph.D., the company’s Chief Business Officer, will present at the upcoming Wells Fargo Healthcare Conference in Boston at 4:30 pm ET on Wednesday, September 6, 2023.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders. The new financing is an upsize to $75 million of the seed round that had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation by new investors Sanofi Ventures, Medical Excellence Capital (MEC), and Astellas Venture Management (AVM).

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today presented new preclinical proof-of-concept data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimera (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia. The company presented in vivo proof-of-concept data in non-human primates showing robust and dose-dependent degradation of a circulating extracellular protein by a monovalent ATAC degrader.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that it will present new in vivo proof-of-concept data from its ATAC (ASGPR Targeting Chimera) degrader platform at two upcoming drug discovery conferences. Kevin Lumb, DPhil, VP Biology, will present at the Discovery on Target Conference being held October 17-20, 2022. Effie Tozzo, PhD, Chief Scientific Officer, will present at the 5th Annual Targeted Protein Degradation Summit being held October 25-28, 2022.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the formation of its Scientific Advisory Board (SAB) comprised of an esteemed group of leading scientists with expertise in protein degradation, chemistry, genetics, and drug discovery. The Avilar SAB will provide guidance to the company as it advances the discovery and development of ATACs (ASGPR Targeting Chimeras) as novel degraders of extracellular proteins involved in the pathogenesis of disease.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that members of the company’s leadership team will be featured speakers on advances in the protein degradation field at two upcoming drug discovery conferences.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs (ASGPR-Targeting Chimeras) at the 5th annual Protein Degradation Using PROTACs & Molecular Glues meeting being held in San Diego, April 19-20. ATACs are a new class of degraders designed to degrade extracellular proteins.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Daniel Grau, CEO and President, will present at the upcoming Guggenheim Targeted Protein Degradation Day at 2:00PM – 2:30PM on Wednesday, March 16, 2022.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a $60 million seed financing from founding investor RA Capital Management. Avilar is creating a novel class of protein degrader therapeutics designed to target disease-causing extracellular proteins, extending the reach of protein degradation beyond initial degraders that target intracellular proteins.